Check for updates

OPEN ACCESS

EDITED BY Gabriela Anaya-Saavedra, Metropolitan Autonomous University, Mexico

REVIEWED BY Jessica Maldonado-Mendoza, Metropolitan Autonomous University, Mexico Marcela Vázquez, Metropolitan Autonomous University, Mexico

*CORRESPONDENCE Eliete Neves Silva Guerra 🖂 elieteneves@unb.br

RECEIVED 05 December 2023 ACCEPTED 22 January 2024 PUBLISHED 02 February 2024

CITATION

Guerra ENS, Amorim dos Santos J, Coletta RD and De Luca Canto G (2024) Strategies for evidence-based in head and neck cancer: practical examples in developing systematic review questions.

Front. Oral. Health 5:1350535. doi: 10.3389/froh.2024.1350535

COPYRIGHT

© 2024 Guerra, Amorim dos Santos, Coletta and De Luca Canto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Strategies for evidence-based in head and neck cancer: practical examples in developing systematic review questions

Eliete Neves Silva Guerra^{1*}, Juliana Amorim dos Santos¹, Ricardo D. Coletta² and Graziela De Luca Canto³

¹Laboratory of Oral Histopathology, Health Sciences Faculty, University of Brasilia, Brasilia, Brazil, ²Department of Oral Diagnosis and Graduate Program in Oral Biology, School of Dentistry, University of Campinas, Piracicaba, Brazil, ³Brazilian Centre for Evidence-Based Research, Department of Dentistry, Federal University of Santa Catarina, Florianópolis, Brazil

A systematic review (SR) requires several steps to be conducted. A major and initial challenge is to formulate a focused research question that may have high scientific relevance to provide evidence-based results and strategies. This narrative mini-review aims to present different categories of systematic reviews currently applied in Head and Neck Cancers (HNC), focusing on the strategies to provide results for evidence-based decision making. The SRs identified were of intervention, diagnostic testing, prognosis, *in vitro* and *in vivo* studies, prevalence, and epidemiological studies, and of association and risk factors. Focused questions that define the type of review, whether it is a therapy question (intervention), a question of prevalence or an outcome (prognosis) of disease, are discussed. Additionally, the importance in building interesting research questions and following all proposed steps to produce quality evidence are highlighted. This narrative mini-review may guide future research by showing how to perform and report relevant evidence in terms of HNC.

KEYWORDS

education and practice, evidence-based, systematic review, meta-analysis, head and neck cancer

1 Introduction


Head and Neck Cancer (HNC) is one of the most prevalent malignancies affecting diverse regions of the oral cavity, larynx, and oropharynx (1). In 2020, the last GLOBOCAN estimative underscored over 714,000 cases of HNC worldwide. Among these, Oral Squamous Cell Carcinoma (SCC) emerges as the most common subtype accounting for 377,713. The anticipated estimative for 2025 predicts a continued rise in HNC cases, reaching over 800,000 cases globally. Notably, 52% of these cases are expected to occur in the oral cavity (2).

The development of HNC involves a complex series of events. Its progression is marked by a gradual genetic and epigenetic variations affecting cell growth, survival, and microenvironment interactions (3). It this context, lifestyle is highlight as a major point. Different forms of tobacco use, including betel quid/areca nut, alcohol consumption, and human papillomavirus (HPV) infection are the most related risk factors (4). Tobacco and alcohol, whether separately or in combination, are mainly associated with oral SCC. Additionally, HPV infection, particularly HPV type 16, has

been associated with oropharyngeal, and ultraviolet radiation sunlight exposure with lip SCC (5, 6).

Considering the importance of HNC, the number of Systematic Reviews (SR) has increased over the years (Figure 1A). In 2022, 662

SRs were dedicated to different aspects of HNC, with the trend difference reaching more than 100 SRs between 2019 and 2020 following PUBMED database search (Figure 1B). Nonetheless, conducting a SR requires experience in translating clinical issues



10.3389/froh.2024.1350535

to a research question considering its maximum efficiency to find relevant evidence. This experience improves the ability to critically evaluate the evidence and apply the results in clinical practice. According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, a SR requires several steps, such as defining a focused question, establishing inclusion and exclusion criteria, searching databases, selecting studies, appraising methodological quality or risk of bias, collect data, and synthesize results (7).

To manage a SR, researchers must be prepared to identify relevant issues that require information synthesis and develop adequate questions to accurately assess the evidence. Thus, the purpose of this article is to present the main principles of methodologies applied to different SR categories on HNC. This narrative mini-review based on authors' experience guides the formulation of questions according to the acronym's strategies for SR.

2 Types of systematic reviews in HNC

2.1 SR of intervention

Interventional SR is a classic and well-known type of review that aims to assess and compare treatment options. The purpose is to summarize evidence regarding the effects of health care or social interventions for certain diseases or conditions. Ideally, it should be performed including randomized clinical trials (RCT) because of its high level of evidence. If there is a lack of RCT, non-RCT studies or observational studies can be included, however the level of evidence is lowered (8).

To illustrate the strategy for a SR of intervention, we can cite the article by Normando et al. (9) which aimed to assess the effects of turmeric and curcumin for oral mucositis. The authors used the acronyms PICOS with detailed explanation to formulate a precise research question (Table 1). Applying this strategy, the study showed strong evidence for the application of turmeric and curcumin in the treatment of chemo/radio induced oral mucositis. Both turmeric and curcumin were able to reduce pain, erythema intensity, ulceration area, and degree of severity of oral mucositis. They were also effective in prevention by delaying the

TABLE 1 PICOS strategy to develop a focused question for SR of intervention.

Main HNC concern	Chemo/radiotherapy induced oral mucositis in HNC		
PICOS strategy for SR of intervention			
Participants or population	Cancer patients undergoing chemotherapy and/or radiotherapy		
Intervention	Turmeric or curcumin		
Comparison or control	Placebo or other interventions		
Outcomes	Prevention or treatment of oral mucositis		
Studies	Clinical trials (randomized or not)		
Final research question	Is there any effect of turmeric and curcumin in the management of oral mucositis induced by chemotherapy and/or radiotherapy in cancer patients?		

onset of the lesions. However, the authors suggest further investigation to improve and confirm de evidence.

2.2 SR of diagnostic testing

Diagnostic tests are used by health professionals to discriminate whether an individual has a particular disease or condition in populations considered to be suspect for the disease (10). It is known that a test is sensitive when it can discriminate among suspects, those who are effectively ill. Sensitivity is the reason of the number of true positive assessments per number of all positive assessments. Differently, specificity is the ability of the same test to be negative, which represents the reason of the number of true negative assessments per number of all negative assessments (11). The SR of diagnostic test allows investigating the validity of an index test compared to a reference test (reference standard), considering different designs of diagnostic studies and different population profiles (10). Thus, the SR of diagnosis is a very important tool to study the applications of new exams and diagnostic methods, taking in consideration accuracy, sensitivity, and specificity measures.

As an example, Guerra et al. (12) aimed to assess the capability of serum biomarkers to diagnose HNC. For this purpose, the acronyms PIRDS were applied with detailed explanations (Table 2). The study was able to demonstrate promising serum biomarkers in the diagnosis of HNC. Accuracy was improved by the combination of EGFR + Cyclin D1 and SCCA + EGFR + Cyclin D1. The results have also shown higher sensitivity and specificity when compared to isolated biomarkers. The authors pointed out the need for further well-structured research to validate these biomarkers.

2.3 SR of prognosis

The SR of prognosis is an excellent tool and widely used in HSC field as it is the most adequate review to summarize overall outcomes. It is also used to determine the importance of an exam to determine the prognosis and to identify prognostic factors and predictors of an individual's response to treatment, associated or not with changes in health outcomes (13).

TABLE 2 PIRDS strategy to develop a focused question for SR of diagnostic testing.

Main HNC concern	Biomarkers for diagnosis of the HNC		
PIRDS strategy for SR of diagnostic testing			
Participants or population	Individuals with HNC		
Index test	Serum (blood) biomarkers		
Reference test	Biopsy followed by histopathological analysis		
Diagnosis of interest	Accuracy, sensitivity, and specificity measures		
Studies	Diagnostic testing studies		
Final research question	Do serum (blood) biomarkers have the capability to accurately identify HNC patients from non-HNC controls?		

TABLE 3 prognosis.	strategy	to	develop	а	focused	question	for	SR	of

Main HNC concern	Prognostic factors associated with survival in HNC		
PICOS strategy for SR of Prognosis			
Participants or population	Individuals with oral cancer		
Intervention or exposure	CAF analysis by immunohistochemical detection with anti- $\alpha\mbox{-}SMA$ antibody		
Comparison or control	Normal tissue (oral mucosa)		
Outcomes	Overall survival and disease-free survival		
Studies	Observational studies in humans		
Final research question	Do immunodetection of cancer-associated fibroblasts (α -SMA-positive fibroblasts) serves as a prognostic factor of the survival of patients with oral cancer?		

CAF, cancer-associated fibroblasts; α -SMA, alpha smooth muscle actine.

Illustrating this type of SR, Dourado et al. (14) evaluated the impact of cancer-associated fibroblasts (CAF) on oral cancer prognosis. The focused question was structured using a PICOS strategy with detailed information (Table 3). Based on that, authors (14) found CAF as an appropriate prognostic biomarker and therapeutic target in oral cancer. The high expression of CAF was associated with worse overall survival and disease-free survival in oral cancer. Moreover, a correlation of the abundance of CAF and the clinicopathological features could be suggested reflecting in aggressiveness and dissemination of this disease.

2.4 SR of in vitro and in vivo studies

In vitro experiments with cell culture and *in vivo* animal models are studies widely used in the research routine of pathology and histology laboratories. SR with these types of studies provide an excellent source for identifying gaps in the translational research, gaining knowledge and ideas to improve laboratory questions. However, it should be noted that SR of *in vitro* and *in vivo* animal studies present a lower level of evidence compared to clinical and observational studies (15). Although there are limitations associated to *in vitro* and *in vivo* SR, it is often necessary to answer about specific topics or when there is no stronger evidence available.

Aiming to assess curcumin as an alternative treatment for HNC, Borges et al. (16) conducted a SR with *in vitro* and *in vivo* studies. Note that the decision to incorporate laboratory studies was driven by the recognition of the lack of evidence on this topic in a clinical context. The focused question was based on a PICOS acronyms (Table 4). In this study, the authors found curcumin as an effective inhibitor of proliferation and survival in HNC cells. The SR also demonstrated its effects on reducing tumor measurements in animal models. While this SR provides an initial level of evidence, it reinforces the potential of curcumin as an adjuvant drug in HNC treatment. The immediate application of these findings to patients may not be feasible, but it supports the initiation of clinical trials based on fundamental evidence.

TABLE 4 PICOS strategy to develop a focused question for SR of laboratorial studies.

Main HNC concern	Cellular response and tumor size in HNC		
PICOS strategy for SR of laboratorial studies			
Participants or population	Cell cultures (in vitro) and animals (in vivo).		
Intervention or exposure	Curcumin		
Comparison or control	Untreated, placebo or substances other than curcumin		
Outcomes	(i) in vitro cell proliferation, viability or cytotoxicity or in vivo tumor volume or tumor incidence and (ii) apoptosis and/or cell cycle arrest, including analysis of protein expression.		
Studies	Experimental in vitro or in vivo animal studies		
Final research question	What are the <i>in vitro</i> effects of curcumin on the proliferation and survival of head and neck squamous cell carcinoma cell cultures and the animal <i>in vivo</i> effect on tumor size?		

2.5 SR of epidemiology studies

SR from epidemiological studies is necessary to regulate health conditions trends in terms of prevalence and incidence. This type of SR can also determine the frequency of clinical, radiographic, or histological findings as signals or symptoms of certain diseases. Data synthesis provided by this type of review is a powerful tool to inform social and healthcare professionals, policymakers, and consumers on the decisionsmaking moment (17).

As an example of SR of prevalence in HNC, we can cite the article by Moura et al. (18). This review serves as a model for frequency surveys regarding pathway mutations. It aimed to define the prevalence of PI3K-AKT-mTOR signaling pathway mutations in patients with HNC. Using the PEOS strategy to formulation a focused question (Table 5), the authors found an estimated mutations prevalence ranging from 2% (*AKT*) to 13% (*PIK3CA*) for the related genes. To make the evidence more robust, they could also perform subgroup analysis according to risk factors and tumor characteristics, including HPV infection, tobacco use, alcohol exposure, TNM stage, and histological tumor differentiation. Moreover, the findings

TABLE 5 PEOS strategy to develop a focused question for SR of epidemiology studies.

Main HNC concern	Prevalence of gene mutations in HNC			
PEOS strategy for SR of prevalence and epidemiology studies				
Participants or population	Individuals with HNC			
Exposure	Mutations in the following genes of the PI3K-AKT-mTOR signaling pathway—PIK3CA, AKT, MTOR, and PTEN			
Outcomes	Prevalence of mutations in the PI3K-AKT-mTOR pathway			
Studies	Observational studies and clinical trials (randomized and non-randomized).			
Final research question	What is the worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer?			

demonstrated that PI3K-AKT-mTOR pathway emerges as a potential prognostic factor and could offer a molecular basis for future studies on therapeutic targeting in HNC patients.

2.6 SR of association and risk factors

SR of association and risk factors assess individuals' characteristics or habits, such as genetic aspects or environmental exposure, and the risk of developing health conditions. The risk factors can be modifiable, for example, cigarette smoke, or non-modifiable – family history (19). Therefore, SR in this field presents important evidence that influences health practice, not only for professional's care decisions, but also for population counselling.

The SR published by Mello et al. (20) is a model of association review using the PECOS strategy (Table 6). This study aimed to answer if there is an association between mate consumption and the occurrence of upper aerodigestive tract (UADT) cancer. As results, they found an increased chance of cancer occurrence in all UADT subsites (oral, pharynx, esophagus, and larynx) when mate consumption was present. Secondary outcomes showed that high volumes of mate consumption per day increased odds of developing UADT; however, the temperature of consumption did not impact its occurrence.

3 Final considerations

SRs and meta-analyses provide huge benefits for human health by contributing to the evidence-based practice, which reduces the gap between research findings and health care practice (21). This type of scientific reports systematically summarizes and critically appraises available evidence regarding specific topics on health fields, resulting in qualified evidence or suggesting future research needs, when data is limited or nonexistent (22). However, the increasing number of published SRs indicates the need to systematize even more the scientific production process (23). In some cases, although methods of SRs and meta-analysis were well developed, the published evidence is not updated, leading to an inability in maintaining its relevancy and accuracy (21). Concerned about the research

TABLE 6 PECOS strategy to develop a focused question for SR of association and risk factors.

Main HNC concern	Association and risk factors for HNC		
PECOS strategy for SR of association and risk factors studies			
Participants or population	Humans		
Exposure	Mate consumption		
Comparison or control	No consumption		
Outcomes	Association with the occurrence of UADT cancer		
Studies	Observational studies (cohort, case-control and cross-sectional)		
Final research question	Is there an association between mate consumption and occurrence of UADT cancer?		

UATD, upper aerodigestive tract.

Since results obtained in SRs may influence healthcare and research decisions, minimizing risks of error and bias is fundamental (22). In this context, we highlight the importance of following all proposed steps to produce quality evidence. Research should begin from the protocol formulation, containing a PICOS (or similar) strategy designed to answer a focused question, which will establish well-defined inclusion/exclusion criteria, and should assess the quality of the evidence provided without missing any steps (7). We also encourage researchers to practice the living SR as a part of the publication protocol. It will help to incorporate relevant new evidence as it becomes available, allowing the opportunity to narrow the evidencepractice gap (24).

This narrative mini-review presents some limitations. Firstly, the content was focused on methodology applications not on reporting specific data results about HNC. Secondly, the systematic reviews included for discussion were selected according to authors experience with these types of studies. Despite that, it summarizes the different types of SR applied in HNC exploring adequate strategies to provide and report results focus on evidence-based decision making.

Author contributions

EG: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft. JA: Conceptualization, Data curation, Investigation, Methodology, Visualization, Writing – review & editing. RC: Conceptualization, Formal Analysis, Funding acquisition, Investigation, Project administration, Supervision, Visualization, Writing – review & editing. GD: Conceptualization, Formal Analysis, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article.

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article. EG, RC and GD are supported by CNPq — National Council for Scientific and Technological Development, Brazil. JA is supported by CAPES — Coordination for the Improvement of Higher Education Personnel, Brazil.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

References

1. Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends, and risk factors. *Br Dent J.* (2022) 233(9):780–6. doi: 10.1038/s41415-022-5166-x

2. The Global Cancer Observatory, GLOBCAN – IARC. Available online at: https://gco.iarc.fr/today/home (accessed January 15, 2024).

3. Ferraguti G, Terracina S, Petrella C, Greco A, Minni A, Lucarelli M, et al. Alcohol and head and neck cancer: updates on the role of oxidative stress, genetic, epigenetics, oral microbiota, antioxidants, and alkylating agents. *Antioxidants.* (2022) 11(1):145. doi: 10.3390/antiox11010145

4. Arboleda LPA, de Carvalho GB, Santos-Silva AR, Fernandes GA, Vartanian JG, Conway DI, et al. Squamous cell carcinoma of the oral cavity, oropharynx, and larynx: a scoping review of treatment guidelines worldwide. *Cancers.* (2023) 15 (17):4405. doi: 10.3390/cancers15174405

5. Louredo BV, Vargas PA, Pérez-de-Oliveira ME, Lopes MA, Kowalski LP, Curado MP. Epidemiology and survival outcomes of lip, oral cavity, and oropharyngeal squamous cell carcinoma in a southeast Brazilian population. *Med Oral Patol Oral Cir Bucal.* (2022) 27(3):e274–84. doi: 10.4317/medoral.25147

 Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. *Med Sci.* (2023) 11(2):42. doi: 10.3390/medsci11020042

7. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guide line for reporting systematic reviews. *Br Med J.* (2021) 372:n71. doi: 10.1136/bmj.n71

8. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane, 2023. Available online at: www.training.cochrane.org/handbook (accessed January 15, 2024).

9. Normando AGC, de Menêses AG, de Toledo IP, Borges GÁ, de Lima CL, Dos Reis PED, et al. Effects of turmeric and curcumin on oral mucositis: a systematic review. *Phytother Res.* (2019) 33(5):1318–29. doi: 10.1002/ptr.6326

10. Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y. Cochrane handbook for systematic reviews of diagnostic test accuracy. Version 2.0 (updated July 2023). Cochrane, 2023. Available online at: https://training.cochrane.org/handbook-diagnostic-test-accuracy/current (accessed January 15, 2024).

11. Zhu W, Zeng N, Wang N. Sensitivity, specificity, accuracy, associated confidence interval and ROC analysis with practical SAS[®] implementations. Northeast SAS Users Group, Health Care and Life Sciences (2010).

12. Guerra EN, Rêgo DF, Elias ST, Coletta RD, Mezzomo LA, Gozal D, et al. Diagnostic accuracy of serum biomarkers for head and neck cancer: a systematic review and meta-analysis. *Crit Rev Oncol Hematol.* (2016) 101:93–118. doi: 10.1111/j.14711842.2009.00848.x

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

13. Riley RD, Moons KGM, Snell KIE, Ensor J, Hooft L, Altman DG, et al. A guide to systematic review and meta-analysis of prognostic factor studies. *Br Med J*. (2019) 30(364):k4597. doi: 10.1136/bmj.k4597

14. Dourado MR, Guerra ENS, Salo T, Lambert DW, Coletta RD. Prognostic value of the immunohistochemical detection of cancer-associated fibroblasts in oral cancer: a systematic review and meta-analysis. *J Oral Pathol Med.* (2018) 47(5):443–53. doi: 10.1111/jop.12623

15. Lander B, Balka E. Exploring how evidence is used in care through an organizational ethnography of two teaching hospitals. *J Med Internet Res.* (2019) 21 (3):e10769. doi: 10.2196/10769

16. Borges GÁ, Rêgo DF, Assad DX, Coletta RD, De Luca Canto G, Guerra EN. *In vivo* and *in vitro* effects of curcumin on head and neck carcinoma: a systematic review. *J Oral Pathol Med.* (2017) 46(1):3–20. doi: 10.1111/jop.12455

17. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Chapter 5: systematic reviews of prevalence and incidence. In: Aromataris E, Munn Z, editors. *JBI Manual for Evidence Synthesis*. JBI (2020). p. 175–215. Available online at: https://synthesismanual.jbi.global.

 Moura AC, Assad DX, Dos Santos JA, de Toledo IP, Barra GB, Castilho RM, Squarize CH, Guerra ENS. Worldwide prevalence of P13K-AKT-mTOR pathway mutations in head and neck cancer: a systematic review and meta-analysis. *Crit Rev Oncol Hematol.* (2021) 160:103284. doi: 10.1016/j.critrevonc.2021.103284

19. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: systematic reviews of etiology and risk. In: Aromataris E, Munn Z, editors. *JBI Manual for Evidence Synthesis*. JBI (2020). p. 217–67. Available online at: https:// synthesismanual.jbi.global.

20. Mello FW, Scotti FM, Melo G, Warnakulasuriya S, Guerra ENS, Rivero ERC. Mate consumption association with upper aerodigestive tract cancers: a systematic review and meta-analysis. *Oral Oncol.* (2018) 82:37–47. doi: 10.1016/j.oraloncology. 2018.04.023

21. Elliott JH, Turner T, Clavisi O, Thomas J, Higgins JP, Mavergames C, et al. Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap. *PLoS Med.* (2014) 11(2):e1001603. doi: 10.1371/journal.pmed.1001603

22. Moola S, Munn Z, Sears K, Sfetcu R, Currie M, Lisy K, et al. Conducting systematic reviews of association (etiology): the joanna briggs institute's approach. *Int J Evid Based Healthc.* (2015) 13(3):163–9. doi: 10.1097/XEB.000000000000064

23. Pollock M, Fernandes RM, Becker LA, Pieper D, Hartling L. Chapter V: overviews of reviews. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. *Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023)*. Cochrane (2023). Available online at: www.training.cochrane.org/handbook

24. Elliott JH, Synnot A, Turner T, Simmonds M, Akl EA, McDonald S, et al. Living systematic review: 1. Introduction-the why, what, when, and how. *J Clin Epidemiol.* (2017) 91:23–30. doi: 10.1016/j.jclinepi.2017.08.010